Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$18.83 -4.5%	$18.67	$13.52 ▼ $35.25	$1.98B	2.22	2.37 million shs	2.71 million shs
KNSA Kiniksa Pharmaceuticals International	$31.98 +5.7%	$28.38	$17.82 ▼ $32.15	$2.21B	0.14	611,693 shs	1.07 million shs
OXBDF Oxford BioMedica	$6.25 +3.8%	$4.69	$3.15 ▼ $6.25	$637.89M	1.08	812 shs	510 shs
TWST Twist Bioscience	$33.68 +0.3%	$34.67	$27.12 ▼ $55.33	$2.01B	2.37	891,336 shs	1.38 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-4.46%	-13.31%	-5.28%	-6.97%	-40.49%
KNSA Kiniksa Pharmaceuticals International	+5.68%	+21.46%	+16.55%	+15.66%	+20.23%
OXBDF Oxford BioMedica	+3.82%	+20.89%	+47.75%	+59.17%	+32.14%
TWST Twist Bioscience	+0.33%	-6.42%	-10.62%	-14.17%	-39.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.6035 of 5 stars	3.5	1.0	0.0	0.0	3.2	2.5	0.6
KNSA Kiniksa Pharmaceuticals International	3.1509 of 5 stars	3.5	3.0	0.0	0.0	2.5	3.3	0.6
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	3.566 of 5 stars	3.4	0.0	0.0	4.4	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.75	158.90% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	28.73% Upside
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A
TWST Twist Bioscience	2.70	Moderate Buy	$50.40	49.64% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, KNSA, TWST, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/6/2025	TWST Twist Bioscience	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
5/6/2025	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/6/2025	TWST Twist Bioscience	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $44.00
5/6/2025	TWST Twist Bioscience	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	29.81	N/A	N/A	$8.86 per share	2.13
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.51	N/A	N/A	$6.78 per share	4.72
OXBDF Oxford BioMedica	$111.34M	5.95	N/A	N/A	$1.01 per share	6.19
TWST Twist Bioscience	$312.97M	6.45	N/A	N/A	$8.07 per share	4.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	799.70	127.92	N/A	0.90%	1.05%	0.80%	N/A
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	-$208.73M	-$3.25	N/A	N/A	N/A	-54.98%	-33.48%	-25.34%	8/4/2025 (Confirmed)

Latest OXBDF, KNSA, TWST, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/4/2025	Q3 2025	TWST Twist Bioscience	-$0.54	N/A	N/A	N/A	$95.52 million	N/A
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/5/2025	Q2 2025	TWST Twist Bioscience	-$0.56	-$0.66	-$0.10	-$0.66	$92.00 million	$92.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.43
OXBDF Oxford BioMedica	N/A	N/A	N/A
TWST Twist Bioscience	0.03	4.51	4.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
KNSA Kiniksa Pharmaceuticals International	53.95%
OXBDF Oxford BioMedica	N/A
TWST Twist Bioscience	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
KNSA Kiniksa Pharmaceuticals International	53.48%
OXBDF Oxford BioMedica	N/A
TWST Twist Bioscience	3.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable
TWST Twist Bioscience	990	59.92 million	58.11 million	Optionable

OXBDF, KNSA, TWST, and BEAM Headlines

Recent News About These Companies

Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 1 at 2:39 AM | americanbankingnews.com

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

July 31 at 6:52 PM | finance.yahoo.com

Is There An Opportunity With Twist Bioscience Corporation's (NASDAQ:TWST) 27% Undervaluation?

July 31 at 4:52 AM | finance.yahoo.com

Is Twist Bioscience Corp. (TWST) Nearing Profitability?

July 28, 2025 | msn.com

Twist Bioscience (TWST) to Release Earnings on Monday

July 28, 2025 | marketbeat.com

Envestnet Asset Management Inc. Has $2.76 Million Position in Twist Bioscience Corporation (NASDAQ:TWST)

July 28, 2025 | marketbeat.com

ARK Investment Management LLC Acquires 645,730 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Sells 197,166 Shares of Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Baillie Gifford & Co. Has $28.74 Million Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 27, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of "Moderate Buy" by Brokerages

July 27, 2025 | marketbeat.com

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

July 25, 2025 | 247wallst.com

Cwm LLC Has $639,000 Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 24, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Position Trimmed by Jennison Associates LLC

July 21, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $21.25 Million Stake in Twist Bioscience Corporation (NASDAQ:TWST)

July 18, 2025 | marketbeat.com

Twist Bioscience Corporation (NASDAQ:TWST) Shares Bought by New York State Common Retirement Fund

July 17, 2025 | marketbeat.com

Principal Financial Group Inc. Trims Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

July 17, 2025 | marketbeat.com

Twist Bioscience: Still Not There Yet

July 15, 2025 | seekingalpha.com

Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

July 14, 2025 | businesswire.com

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis Sells 2,449 Shares

July 11, 2025 | marketbeat.com

Emily M. Leproust Sells 476 Shares of Twist Bioscience Corporation (NASDAQ:TWST) Stock

July 8, 2025 | insidertrades.com

Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) CEO Sells 476 Shares of Stock

July 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXBDF, KNSA, TWST, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$18.83 -0.88 (-4.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.98 +0.15 (+0.80%)

As of 08/1/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$31.98 +1.72 (+5.68%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$32.79 +0.81 (+2.54%)

As of 08/1/2025 08:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Oxford BioMedica OTCMKTS:OXBDF

$6.25 +0.23 (+3.82%)

As of 08/1/2025 02:57 PM Eastern

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Twist Bioscience NASDAQ:TWST

$33.68 +0.11 (+0.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$33.98 +0.30 (+0.89%)

As of 08/1/2025 06:52 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time